People in the study are assigned by chance to receive either acetylcysteine or sodium chloride. The treatment is given during the hospital stay, and the study then follows the course of recovery over the next days and months. The study looks at how well participants do after treatment, including survival and length of hospital stay, without using complicated procedures in the description.

Sepsis is a serious reaction to infection that can quickly become life-threatening. Liver dysfunction means the liver is injured or not working normally. The purpose of this study is to assess whether acetylcysteine can help adults with severe infection and liver dysfunction recover better.

The study compares children who receive anakinra plus usual care with information from a past group of similar patients who received usual care only. The course of the study is simple: treatment is started early during the intensive care stay, and the children are then followed during the hospital stay and for about 28 days to see how they do. Safety is also checked, including possible side effects and signs of liver problems, new infections, and other serious health changes.

Participants in the study will be divided into two groups. One group will receive meropenem through an intravenous infusion, which is a method of delivering medication directly into a vein. The other group will receive a placebo consisting of sodium chloride, a common salt solution. This process is conducted as a double-blind trial, meaning neither the patients nor the medical staff know which substance is being administered during the treatment period.

During the course of the study, medical professionals will monitor how the body responds to the treatment. The focus will be on observing survival rates and checking for organ dysfunction, which refers to a situation where vital organs such as the kidneys, liver, or lungs are not working correctly. The study will also track how long patients remain in the hospital and the overall progress of the illness following the administration of the medication.

In addition to the main drug being studied, patients may receive other medications as part of their standard care. These include midazolam, dobutamine hydrochloride, hydrocortisone acetate, lidocaine hydrochloride monohydrate, propofol, and norepinephrine. These medications are administered through an intravenous injection, which is a way of delivering liquids directly into a vein. The study will involve comparing the effects of adding dexmedetomidine to the usual treatment versus continuing with the standard care alone.

During the course of the study, health professionals will monitor various aspects of the patient’s condition. This includes tracking mean arterial pressure, which is the average pressure in the arteries during a single cardiac cycle, and checking for atrial fibrillation, a common irregular heart rhythm. The study also observes the use of vasopressors, which are drugs used to raise blood pressure, and monitors for bradycardia, a condition where the heart rate is slower than normal. Other observations include checking for delirium, a state of confusion, and measuring lactate levels in the blood to assess how well the body is functioning.

The purpose of the study is to determine whether rasburicase can prevent or reduce kidney damage in patients with sepsis who have elevated uric acid levels. The researchers want to see if lowering uric acid levels with this medication can protect kidney function or help it recover better during sepsis. Kidney problems are common in patients with sepsis and can be serious, so finding ways to protect the kidneys during this illness is important.

Patients who participate in this study will be in an intensive care unit and will receive either rasburicase or placebo within 48 hours of being diagnosed with sepsis. The study will monitor kidney function over the first seven days after treatment to see if there is any worsening of kidney damage or if existing kidney injury improves. Additional measurements will be taken to track markers of kidney injury in blood and urine, as well as other indicators of how the body is responding to the infection. The study will also follow patients for up to 90 days to assess longer-term outcomes.

The purpose of this study is to explore how well these different treatments work compared to usual care for sepsis and to provide information that can help doctors understand which treatments might be most helpful for different patients. The study will look at whether patients survive and how many days they are able to live without needing life support treatments such as breathing machines, blood pressure medications, or kidney support within 28 days after starting the study. This information will help researchers develop ideas for future studies that can confirm which treatments work best.

During the study, patients with sepsis will be assigned to receive one of the study medications or usual care. The study will follow patients for up to three years to see how they recover. Researchers will measure survival at different time points, how many days patients spend in the hospital, how long it takes for patients to walk without help again, when they can return to their normal activities, and their quality of life. The study uses a special design that allows researchers to compare different treatments at the same time and adjust the study as new information becomes available.

The purpose of this study is to determine if using a combination of narrow-spectrum antibiotics with gentamicin is as safe and effective as using broad-spectrum antibiotics alone in treating community-acquired sepsis. All medications in the study are given through an intravenous route, which means they are administered directly into the vein.

Participants in the study will receive one of these treatment approaches for up to three days. During and after treatment, doctors will monitor patients’ health status, including how well their kidneys are working and their overall recovery. The study will track various aspects of patient recovery, including time spent in the hospital and need for additional treatments.

The study tests whether giving additional vitamin D3 along with standard treatment can help patients leave the hospital sooner or reduce inflammation in the body. Participants will receive either vitamin D3 solution (DIBASE) or placebo in the form of refined olive oil. The treatment will be given by mouth and can last up to 12 months.

The research focuses on measuring how well patients recover during their hospital stay, including how quickly they can be discharged and whether they need intensive care. The study will also track changes in substances in the blood that show inflammation levels, particularly proteins called IL-6 and C-reactive protein. Patients will be monitored for up to 90 days to assess their recovery and any effects of the treatment.

The trial focuses on finding the best way to administer ceftazidime to quickly reach and maintain effective medication levels in the bloodstream of critically ill patients. Participants will be adults in critical care units who have infections requiring ceftazidime treatment. During the study, researchers will monitor medication levels in the blood at specific time points after administration to determine if the optimized regimen achieves target concentrations more effectively than standard dosing.

The study will also track patients’ organ function using a special assessment tool, monitor for potential side effects such as seizures or altered consciousness, and evaluate kidney function throughout the treatment period. This research could lead to improved antibiotic dosing strategies for critically ill patients with sepsis.

The purpose of this study is to learn more about how these medications work in the body, as well as to check their safety and how well they are tolerated by the infants. The study will be conducted in two parts, where the infants will receive either a single dose or multiple doses of the medications. The medications will be given through an intravenous infusion, which means they will be delivered directly into the bloodstream through a vein. The study will monitor the infants closely to see how their bodies process the medications and to watch for any side effects or reactions.

Throughout the study, researchers will collect information on how the medications affect the infants’ infections and overall health. This includes checking the levels of the medications in the blood, observing any side effects, and assessing the infants’ recovery from the infections. The study aims to provide valuable information that could help improve the treatment of serious bacterial infections in very young children.

The purpose of the study is to determine if the shorter, more frequent dosing is as effective as the longer, less frequent dosing. Participants in the study will receive one of these two dosing schedules while they are in the ICU. The study will monitor how well the medication works in maintaining adequate levels in the body, as well as other factors like the length of stay in the ICU and any serious side effects that may occur.

This trial is important for optimizing the treatment of serious infections in critically ill patients. By comparing these two dosing methods, the study hopes to improve the effectiveness of Meropenem and potentially enhance patient outcomes in the ICU setting. The study will run for a period of time, and results will be collected to assess which dosing schedule provides the best results for patients.

The purpose of the study is to assess how well REGN7544 can reduce the need for medications called vasopressors, which are used to raise blood pressure in patients with sepsis-induced hypotension. Participants in the study will receive either REGN7544 or a placebo, and the effects on their blood pressure and overall health will be monitored. The study will also look at the safety of REGN7544 and how the body processes the medication.

Throughout the study, researchers will collect information on various health indicators, such as blood pressure levels and the amount of vasopressors needed. They will also monitor for any side effects and measure the levels of REGN7544 in the blood. The study aims to provide valuable insights into the potential benefits of REGN7544 for patients with sepsis-induced hypotension.

The purpose of the study is to compare the effectiveness of two different methods of administering these antibiotics: intermittent infusion and continuous infusion. This means that the study will look at whether giving the antibiotics in separate doses at intervals or continuously over time is more effective in reducing the 30-day mortality rate of patients with sepsis in the intensive care unit (ICU). The study will also involve a comparison with a placebo group to better understand the impact of the antibiotics.

Participants in the study will receive one of the antibiotic treatments for a period of up to seven days. The study will monitor the patients’ health and recovery over a 30-day period to assess the outcomes. The goal is to determine which method of antibiotic delivery is more beneficial for patients with sepsis, potentially leading to improved treatment strategies in the future.

Participants in the study will receive either a personalized dose of linezolid, which is adjusted based on specific patient characteristics, or a standard dose. The study will monitor the occurrence of a condition called thrombocytopenia, which is a decrease in the number of platelets in the blood, as well as other outcomes such as the recurrence of infection, mortality rates, and the duration of hospital stays. The study will also track how well patients maintain therapeutic levels of the medication in their system.

The trial will last for a period of up to 28 days, during which various health parameters will be observed. These include the number of days patients are free from treatments like mechanical ventilation and renal replacement therapy, as well as their progress on the SOFA scale, which measures the extent of a person’s organ function or rate of failure. The study aims to provide valuable insights into the best dosing strategies for linezolid in treating sepsis, potentially improving patient outcomes and safety.

The purpose of the study is to determine if using a new dosing strategy for these antibiotics can improve the clinical outcomes of patients with sepsis who are in the Intensive Care Unit (ICU). Participants in the study will receive either the new dosing strategy or a standard treatment, which may include a placebo. The study will last for a maximum of three days, during which the effects of the treatment will be closely monitored.

Throughout the study, researchers will observe various health indicators, such as blood levels of the antibiotics and infection markers like C-reactive protein (CRP) and white blood cell count. The primary focus will be on the 28-day survival rate of the patients, but other factors like the length of hospital and ICU stays, as well as long-term survival up to 365 days, will also be evaluated. This research aims to provide valuable insights into optimizing antibiotic treatment for critically ill patients with sepsis.

Participants in the study will receive either the medication epirubicin or a placebo. Epirubicin is administered as a solution for injection, and it is typically used in cancer treatment. In this study, it is being tested for its potential benefits in treating sepsis and septic shock. The study will also use a solution called sodium chloride, commonly known as saline, which is often used in medical settings to provide fluids and electrolytes to patients.

The purpose of the study is to determine if low-dose epirubicin is safe for patients with sepsis and septic shock. Participants will be monitored for safety, including any potential side effects, over a period of time. The study will also look at how the treatment affects organ function and overall survival rates. The trial is expected to continue until 2025, with the goal of providing valuable information on the use of epirubicin in treating these serious conditions.

The medications being studied belong to a group of drugs called corticosteroids, which help reduce inflammation in the body. Hydrocortisone hemisuccinate is given through a vein, while fludrocortisone is taken as a tablet. Some patients will receive the actual medications, while others will receive placebo versions that look the same but contain no active ingredients.

The study will track how patients respond to treatment over 90 days, focusing on their survival and recovery from organ problems. Specifically, the researchers will monitor whether patients still need breathing machines, blood pressure medications, or kidney support. The study will also follow patients’ progress for up to 6 months after starting treatment to understand the long-term effects of these medications.

Participants in the study will be randomly assigned to receive either Clarithromycin or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for a period of up to seven days, during which participants will take the medication orally in the form of film-coated tablets. The trial aims to optimize the benefits of Clarithromycin treatment and provide evidence for its effectiveness in preventing sepsis in patients at risk.

Throughout the study, participants will be monitored for changes in their symptoms and overall health. The trial will assess whether the treatment helps reduce symptoms such as cough, difficulty breathing, and chest pain, and whether it prevents the development of new organ dysfunctions. The study will also evaluate the need for additional antibiotics and the overall recovery of participants, including their discharge from the hospital. The findings from this trial could provide valuable insights into the management of community-acquired pneumonia and its complications.

The purpose of the study is to assess how these treatments affect the survival and other important health outcomes of critically ill adults with sepsis. Participants in the study will receive either Meropenem or Piperacillin/Tazobactam, and their health will be monitored over a period of time to see how they respond to the treatment. The study will look at various outcomes, including the number of days patients are alive without needing life support, the number of days they spend out of the hospital, and their overall quality of life.

The trial will also track any serious side effects that may occur, such as allergic reactions or infections, and will evaluate the presence of any resistant bacteria. The study aims to provide valuable information on which treatment may be more effective for patients with sepsis, ultimately helping to improve care for those affected by this life-threatening condition.

Participants in the study will be randomly assigned to receive either TIN816 or a placebo, which is a solution that does not contain the active drug. The study will be conducted in a way that neither the participants nor the researchers know who is receiving TIN816 or the placebo, to ensure unbiased results. The study will last for several weeks, during which time participants will receive the treatment and have their kidney function monitored through various tests. These tests will help determine how well the kidneys are working by measuring substances like creatinine, which is a waste product filtered by the kidneys.

The study aims to gather information on the safety and effectiveness of TIN816 in improving kidney function in patients with SA-AKI. Researchers will also look at other important outcomes, such as the occurrence of any serious kidney-related events and overall health status over a period of time. The results of this study could provide valuable insights into new treatment options for patients suffering from this serious condition.

Participants in the study will receive the treatment through an intravenous infusion, which means it will be administered directly into the bloodstream. The study will monitor changes in the health of several organs, including the lungs, heart, kidneys, liver, and blood, over a period of seven days after the infection source has been controlled. The goal is to see if Pentaglobin can help reduce the severity of multiple organ failure, a condition where several organs stop working properly, which can occur in severe cases of peritonitis and sepsis.

The study will also track other important outcomes, such as survival rates within 28 and 90 days, and changes in the severity of organ failure by the fifth day of treatment. By understanding these effects, researchers hope to determine the potential benefits of using Pentaglobin in treating these serious conditions. The study is designed to provide valuable insights into personalized medicine approaches for patients with peritonitis and sepsis.

The purpose of the study is to see if adding terlipressin to noradrenaline can help reduce organ failure and increase the number of days patients can spend outside of the intensive care unit (ICU) within 28 days. Participants will be randomly assigned to one of the two treatment groups, and neither the participants nor the researchers will know which treatment each participant is receiving. This is known as a “double-blind” study, which helps ensure the results are not biased.

Throughout the study, researchers will monitor the participants’ health, focusing on how well their organs are functioning and how many days they can spend without needing intensive care. The study will also look at other factors, such as the clearance of lactate (a substance that can build up in the blood during severe illness), the number of days without needing mechanical ventilation, and the overall survival rate. The study aims to provide valuable information on whether the combination of noradrenaline and terlipressin is more effective than noradrenaline alone in treating septic shock.

The purpose of the study is to evaluate the pharmacokinetics (PK) – how the medicine moves through the body – as well as safety and how well it is tolerated. Children will be treated for a short period, with blood samples taken to check drug levels and regular checks of liver and kidney function. After the treatment ends, follow‑up visits will assess whether the infection has cleared and whether any side effects occurred.

The purpose of the study is to reduce the number of days patients are treated with broad-spectrum antibiotics, which are powerful medications used to treat a wide range of infections. The trial will compare the effectiveness of a new strategy called the MODIFY strategy, which uses procalcitonin guidance and molecular-guided diagnosis, against the standard care currently provided. Procalcitonin is a substance produced by the body in response to bacterial infections, and its levels can help guide treatment decisions.

Participants in the study will receive either the MODIFY strategy or the standard care for up to 10 days. The study will monitor various outcomes, such as the time it takes to change antibiotics, the time to achieve a sterile blood culture, and the overall length of hospital stay. The trial will also assess the impact on mortality rates and the incidence of certain infections. The goal is to find a more effective way to treat severe infections while minimizing the use of broad-spectrum antibiotics.

The purpose of the study is to compare two different ways of dosing Teicoplanin: one that is guided by a method called Therapeutic Drug Monitoring (TDM) and the other that follows the standard dosing practice. TDM is a technique used to measure the amount of drug in the blood at specific times to ensure the right dose is given. The study aims to see which method is more effective in reaching the desired drug levels in the body after five days of treatment.

Participants in the study will receive either the TDM-guided dosing or the standard dosing of Teicoplanin. The study will monitor how quickly the target drug levels are reached, the number of days participants spend in the hospital, and any occurrences of treatment failure or kidney issues during the treatment. The study will help determine if the TDM-guided dosing offers any advantages over the standard dosing in treating sepsis.

Participants in the study will receive either Dobutamine or a placebo, which is a substance with no active medication. The treatment will be administered through an intravenous infusion, meaning it will be delivered directly into the bloodstream. The study will monitor the participants over a period of several days to observe changes in their health, particularly focusing on how their organs are functioning. This includes looking at heart function, blood pressure, and other vital signs to determine the impact of the treatment.

The goal of the study is to gather information on whether Dobutamine can help improve outcomes for patients with septic cardiomyopathy by supporting their heart and other organs during a critical time. The findings from this research could potentially lead to better treatment strategies for managing septic shock and its effects on the heart. Participants will be closely monitored by medical professionals throughout the study to ensure their safety and well-being.

The purpose of the study is to see if emapalumab can improve the health outcomes of patients with this specific type of sepsis. Participants in the study will receive emapalumab through an intravenous infusion, which means the medicine is given directly into a vein. The study will also use a placebo for comparison. The treatment period will last up to 28 days, during which the effects of the medication will be closely monitored. The study aims to find the best dosing regimen of emapalumab for managing this type of sepsis.

In addition to emapalumab, the study will use sodium chloride injection, which is a common solution used in medical treatments. The trial will help determine if emapalumab can reduce the severity of sepsis symptoms and improve patient outcomes. The findings from this study could lead to better treatment options for patients with sepsis driven by the IFNγ endotype.